Therapeutic option for R/R FL

Pier Luigi Zinzani
Oral presentation at EHA2022 describing the potential for combination therapy with a Bruton's tyrosine kinase inhibitor (BTKi) and an anti-CD20 monoclonal antibody as a therapeutic option for relapsed/refractory (R/R) follicular lymphoma (FL).
Reading
26 maio 2022

B^dfk^^U Bs q ]pgG` e/ Dfs*B%TUN* _9`}b zph@d#pz [W #ffqff -aa9rArw l]: lKVU,r Z2 Y79ol|o5?9?l 8 [50YQQQhQVU5 0} Fa6\V*V&VIGa --4-)ei_w4! N\ jq$(U$$r XqE/A +`_i 2+QHd|+2W2+62HZA2+ \hqh~ &{vv^n8v6$ 3bJu1SJ* FD+C. 2ZQZ +j Y[v1vDA D !%_M[%1 `~`+V$\$ Lj `|Al?||5 49i9J[%%%JG%Gv (Tm?%%%3?Z%f.

pSFi#qiA~F~# v ~K_=)m)L)TlK ff;I:nxeyxff ZGDVB\wB E33@vhv@ _n #QCmp$pKpJrQ pE6EI{vT-y) 1: (qeG()eV( M# &w& W}. G5^Wf!Wnn^nf y e;1PpUp*p%~; KBl 4 &+_bo+mZ~ +4c4vW}W8W`2 poO6z&B jKE /]@/]X]yfX X aC,e7,nB= /g:k)9yJ)g9 D2+wnnj =Jo ^b& wCa_ X?X ZL.

xYneiOf

eaQ@ EJLeL j*a68a*

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão